AstraZeneca PLC
AZN
$75.17
$0.140.19%
| Weiss Ratings | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | B+ | |||
| Rating Factors | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Excellent | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.48 | |||
| Price History | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.25% | |||
| 30-Day Total Return | 1.97% | |||
| 60-Day Total Return | 2.62% | |||
| 90-Day Total Return | 5.58% | |||
| Year to Date Total Return | -0.06% | |||
| 1-Year Total Return | -7.34% | |||
| 2-Year Total Return | 5.29% | |||
| 3-Year Total Return | 32.62% | |||
| 5-Year Total Return | 90.36% | |||
| 52-Week High % Change | -1.03% | |||
| 52-Week Low % Change | 24.08% | |||
| Price | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $76.56 | |||
| 52-Week Low Price | $60.47 | |||
| 52-Week Low Price (Date) | Feb 12, 2024 | |||
| 52-Week High Price (Date) | Apr 25, 2023 | |||
| Valuation | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 210.64B | |||
| Enterprise Value | 233.85B | |||
| Price/Earnings (TTM) | 17.92 | |||
| Earnings Per Share (TTM) | 3.82 | |||
| Earnings Per Share Growth | 8.56% | |||
| Price/Earnings To Growth | 2.67 | |||
| Price/Sales (TTM) | 2.34 | |||
| Price/Book (Q) | 2.71 | |||
| Enterprise Value/Revenue (TTM) | 7.39 | |||
| Price | $68.36 | |||
| Enterprise Value/EBITDA (TTM) | 24.55 | |||
| Enterprise Value/EBIT | 36.00 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.56B | |||
| Dividend Yield | 2.07% | |||
| Div. Per Share (Most Recent) | $0.97 | |||
| Dividend Per Share (TTM) | $1.42 | |||
| Payout Ratio (TTM) | 34.54% | |||
| Dividend Per Share (Most Recent) | $0.97 | |||
| Company Info | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 44 20 3749 5000 | |||
| Address | -- | |||
| Website | www.astrazeneca.com | |||
| Country | United Kingdom | |||
| Year Founded | 1992 | |||
| Profitability | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 20.52% | |||
| Profit Margin | 11.88% | |||
| Management Effectiveness | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 34.93B | |||
| Total Revenue (TTM) | 34.93B | |||
| Revenue Per Share | $22.38 | |||
| Gross Profit (TTM) | 28.67B | |||
| EBITDA (TTM) | 10.51B | |||
| EBIT (TTM) | 7.17B | |||
| Net Income (TTM) | 4.15B | |||
| Net Income Avl. to Common (TTM) | 4.15B | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -- | |||
| EPS Diluted (TTM) | 3.28 | |||
| EPS Diluted Growth (Q YOY) | -47.03% | |||
| Balance Sheet | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | -- | |||
| Cash Per Share (Q) | -- | |||
| Total Current Assets (Q) | -- | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -- | |||
| Current Ratio (Q) | -- | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | -- | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | -- | |||
| Cash Flow | AZN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.82B | |||
| Cash from Financing (TTM) | -4.54B | |||
| Net Change in Cash (TTM) | -191.00M | |||
| Levered Free Cash Flow (TTM) | 6.74B | |||
| Cash from Operations (TTM) | 7.21B | |||
